• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Development of an Orodispersible Film Containing Stabilized Influenza Vaccine

tetano

Editor, Senior Moderator
Pharmaceutics. 2020 Mar 8;12(3). pii: E245. doi: 10.3390/pharmaceutics12030245.
Development of an Orodispersible Film Containing Stabilized Influenza Vaccine.


Tian Y[SUP]1[/SUP], Bhide YC[SUP]1,[/SUP][SUP]2[/SUP], Woerdenbag HJ[SUP]1[/SUP], Huckriede ALW[SUP]2[/SUP], Frijlink HW[SUP]1[/SUP], Hinrichs WLJ[SUP]1[/SUP], Visser JC[SUP]1[/SUP].

Author information




Abstract

Most influenza vaccines are administered via injection, which is considered as user-unfriendly. Vaccination via oral cavity using an orodispersible film (ODF) might be a promising alternative. To maintain the antigenicity of the vaccine during preparation and subsequent storage of these ODFs, sugars such as trehalose and pullulan can be employed as stabilizing excipients for the antigens. In this study, first, β-galactosidase was used as a model antigen. Solutions containing β-galactosidase and sugar (trehalose or trehalose/pullulan blends) were pipetted onto plain ODFs and then either air- or vacuum-dried. Subsequently, sugar ratios yielding the highest β-galactosidase stability were used to prepare ODFs containing H5N1 whole inactivated influenza virus vaccine (WIV). The stability of the H5N1 hemagglutinin was assessed by measuring its hemagglutination activity. Overall, various compositions of trehalose and pullulan successfully stabilized β-galactosidase and WIV in ODFs. WIV incorporated in ODFs showed excellent stability even at challenging storage conditions (60 ?C/0% relative humidity or 30 ?C/56% relative humidity) for 4 weeks. Except for sugars, the polymeric component of ODFs, i.e., hypromellose, possibly improved stability of WIV as well. In conclusion, ODFs may be suitable for delivering of WIV to the oral cavity and can possibly serve as an alternative for injections.



KEYWORDS:

hemagglutination; orodispersible films; pullulan; stabilization; trehalose; whole inactivated influenza virus vaccine; β-galactosidase


PMID:32182676DOI:10.3390/pharmaceutics12030245
Free full text
 
Back
Top Bottom